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Gemtuzumab ozogamicin (Mylotargs) induces remission in
approximately 30% of relapsed AML patients. We previously
demonstrated that gemtuzumab infusion results in near-
complete CD33 saturation in peripheral blood, and that
saturating gemtuzumab levels result in continuous binding
and internalization of gemtuzumab due to renewed CD33
expression. We now demonstrate that a high CD33-antigen
load in peripheral blood is an independent adverse prognostic
factor, likely due to peripheral consumption of gemtuzumab.
Indeed, CD33 saturation in bone marrow is significantly
reduced (40–90% saturation) as compared with CD33 saturation
in corresponding peripheral blood samples (490%). In vitro,
such reduced CD33 saturation levels were strongly related with
reduced cell kill. Apparently, high CD33-antigen loads in blood
consume gemtuzumab and thereby limit its penetration into
bone marrow. Consequently, CD33 saturation in bone marrow
is reduced, which hampers efficient cell kill. Therefore,
gemtuzumab should be administered at higher or repeated
doses, or, preferably, after reduction of the leukemic cell
burden by classical chemotherapy.
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Introduction
Gemtuzumab ozogamicin (Mylotargs) is a humanized CD33
antibody linked to the antitumor antibiotic calicheamicin.1 In
phase-II clinical trials, gemtuzumab administered as single agent
at two doses of 9 mg/m2 2 weeks apart, resulted in complete
remission in approximately 30% of relapsed AML patients.2,3
Gemtuzumab therapy was related with low toxicity, the major
complication being occurrence of hepatic veno-occlusive
disease (VOD) in a small number of patients.4 Based on these
results, gemtuzumab was FDA-approved for treatment of
relapsed AML patients over 60 years of age.5
We have previously shown that after intravenous infusion of
gemtuzumab, near-complete saturation (490%) of CD33-
antigens is achieved on AML blast cells present in peripheral
blood (PB).6 In addition, gemtuzumab also binds to CD33-
antigens expressed by monocytes and granulocytes present in
PB at the time of infusion.6 Consequently, the total amount of
gemtuzumab bound to CD33-antigens in PB depends on the
number of CD33-positive monocytes, granulocytes, and AML
blast cells as well on the CD33 expression level of these cells
(referred to as the peripheral CD33-antigen load). After binding
of gemtuzumab to CD33-antigens, the CD33-antigen/gemtuzu-
mab complexes are rapidly internalized,6 followed by hydrolysis
of the acid-labile linker and subsequent activation of the
calicheamicin g1 derivate.
1 Of importance, upon internalization
of the complexes, new CD33-antigens are rapidly expressed on
the cell surface and subsequently can bind gemtuzumab. The
rate of renewed CD33-antigen expression is related to the
degree of CD33 saturation and internalization6 and to the
activation status of the cell.7 Consequently, the process of CD33
saturation, internalization, and new CD33-antigen expression is
ongoing as long as saturating gemtuzumab concentrations are
maintained. This continuous process will result in a progressive
intracellular accumulation of gemtuzumab.
Obviously, high levels of intracellularly accumulated cali-
cheamicin are more toxic than low levels. Indeed, patients with
less than 5% AML blasts in their PB after the first gemtuzumab
infusion had higher maximal gemtuzumab binding levels on
AML blast cells (ie stronger CD33-antigen expression) than
patients with more than 5% AML blasts in PB after the first
infusion.6 However, no relation was found between CD33
expression levels and clinical outcome as assessed by analysis of
bone marrow (BM) samples.2,3 Apparently, the gemtuzumab
response in PB, but not in BM, is related to the CD33 expression
level on AML blasts.
We hypothesized that high CD33-antigen loads in peripheral
blood consume intravenously administered gemtuzumab, there-
by limiting gemtuzumab concentrations in BM. As a conse-
quence, CD33 saturation of AML blasts in BM might be reduced,
resulting in greatly reduced intracellular accumulation of
gemtuzumab and thereby in inefficient cell kill.
Materials and methods
Patients
Patients enrolled in the gemtuzumab phase-II clinical protocols
0903B1-202-EU (n¼ 54) and 0903B1-203-EU (n¼ 38) were
studied.2,3,6 In these open, single-arm multicenter phase-II
studies, gemtuzumab (Wyeth-Ayerst Laboratories, St Davids,
PA, USA) was administered as a single 2-h intravenous infusion
at a dose of 9 mg/m2. In general, each patient received two
gemtuzumab doses with at least 14 days between the doses.
Prior to the start of each gemtuzumab treatment cycle and 3 and
6 h after the start of each gemtuzumab treatment cycle, PB
samples were obtained, immediately placed on ice (41C) and
shipped overnight at 41C to Immunology, Erasmus MC,
Rotterdam by express courier (World Courier, Hoofddorp, The
Netherlands).
Six patients treated with gemtuzumab on compassionate use
basis were also included in this study. BM samples were taken
prior to and 24 h after gemtuzumab infusion. The latter sample
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was immediately diluted in 200-ml ice-cold phosphate-buffered
saline and kept on ice until further analysis to limit additional
CD33 saturation due to the presence of gemtuzumab in
contaminating PB. PB samples were taken just prior to
gemtuzumab infusion and 6 and 24 h thereafter. Inclusion of
additional patients treated with gemtuzumab as a single agent
and at a dose of 9 mg/m2 was not possible, because current
European clinical trails employ another gemtuzumab dose and/
or use a combination regimen with chemotherapy.
Analysis of CD33 expression, CD33 saturation, and
maximal gemtuzumab binding
Analysis of CD33 expression, CD33 saturation, and maximal
gemtuzumab binding was performed as described previously
using a flow cytometric assay.6 Briefly, to determine CD33
saturation cells were incubated with biotin-conjugated mouse
anti-human IgG4 antibodies (Caltag Laboratories, Burlingame,
CA, USA), followed by streptavidin-FITC (Biosource, Nivelles,
Belgium) as a second step reagent. To detect maximal
gemtuzumab binding, cells were first incubated with excess
gemtuzumab (final concentration: 10mg/ml), followed by
successive incubation with biotin-conjugated mouse anti-hu-
man IgG4 antibodies and streptavidin-FITC. As a negative
control, cells were incubated with streptavidin-FITC alone. To
detect CD33 antigenic sites not occupied by gemtuzumab, cells
were incubated with CD33-PE (clone P67.6; BD Biosciences,
San Jose, CA, USA) or, as a negative control, IgG1-PE (BD
Biosciences). All incubations were performed at 41C. CD45-
PerCP (2D1; BD Biosciences) and/or CD14-PE (My4; Coulter
Clone, Hialeah, FL, USA) antibodies were included to distin-
guish between various cell populations.
To determine the relation between gemtuzumab concentra-
tion and CD33 saturation, the AML193 cell line or PB from
healthy volunteers was incubated with various gemtuzumab
concentrations (15 min at 41C), after which CD33 saturation was
analyzed.
Analysis of peripheral CD33-antigen load
Samples taken just prior to gemtuzumab infusion were subjected
to routine morphological analysis to assess the leukocyte
differential. In addition, maximal gemtuzumab binding to AML
Table 1 Results of statistical analysis for prognostic factors
Analysis Prognostic variablea Univariate analysisb Multivariate analysisc
CR(p) vs NRd Age 0.566 n.d.
FAB 0.508 n.d.
Percentage blasts in BM 0.046 0.272
Multidrug resistance efflux 0.888 n.d.
ECOG performance status 0.600 n.d.
Duration of CR1 0.009 0.201
CD33-antigen load PB 0.001 0.014
aFor details Sievers et al.3
bMann–Whitney U-test.
cLogistic regression.
dCR(p): patients in complete remission, with or without full recovery of platelets (n¼ 18); NR: nonresponders (n¼74).
Figure 1 CD33 saturation levels in BM. (a) CD33 saturation on
AML blast cells in BM and PB samples obtained prior to and 24 h after
gemtuzumab infusion in six AML patients. Before gemtuzumab
infusion, only background CD33 saturation levels (o20%) were
observed in BM. For comparison, previously published CD33
saturation levels in PB prior to gemtuzumab infusion (mean7s.d.)
are shown as well.6 At 24 h after gemtuzumab infusion, CD33
saturation levels in PB were near-complete (mean: 92%), whereas
CD33 saturation levels in BM were significantly lower (mean: 74%;
Po0.05 by Mann–Whitney test). The horizontal bars indicate the
mean CD33 saturation. (b) Relation between CD33 saturation by AML
blast cells in BM and CD33 expression by blast cells for the same
patients. High CD33 expression levels were related to lower CD33
saturation, suggesting that also the CD33-antigen load in BM
contributes to CD33 saturation in BM (Pearson’s Correlation:
0.867; Po0.05). The six patients analyzed in our study all died:
five due to disease progression and one due to stroke. Two patients
(with 61 and 80% CD33 saturation in bone marrow) showed an initial
response after gemtuzumab infusion, characterized by a strong
reduction in blast cells in peripheral blood (to levels o2%). Both
patients, however, showed a fast increase in blast cells in peripheral
blood 1–2 weeks later. It can be speculated that this is due to
outgrowth of AML blast cells in BM, which were not sufficiently
saturated with gemtuzumab for efficient induction of cell kill.
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blast cells, monocytes, and granulocytes was determined as
described above. The peripheral CD33-antigen load was
subsequently calculated as follows: (maximal gemtuzumab
binding blasts #blasts/l)þ (maximal gemtuzumab binding
monocytes #monocytes/l)þ (maximal gemtuzumab binding
granulocytes #granulocytes/l).
Analysis of cell kill
To determine the relationship between induction of cell kill and
gemtuzumab concentration, AML193 cells were incubated with
various gemtuzumab concentrations for 24 or 40 h, after which
cell kill was determined by 51Cr release assay as described
previously.7,8 As AML193 cells also can take up gemtuzumab via
CD33-independent mechanisms (that will contribute to its final
cytotoxic activity),7 an isotype-matched calicheamicin-conju-
gated antibody was not included as a control. To determine
whether free calicheamicin (eg due to hydrolysis of the linkers
during the incubation period) could contribute to cell kill, pilot
experiments using free calicheamicin were performed. These
experiments showed that the maximal amount of free calichea-
micin that could be present during the incubation period
(o0.015mg/ml at the highest gemtuzumab dose; based on less
than 1% free drug in clinical grade gemtuzumab and an estimated
increase with maximally 2–3% in 24 h; P Hamann, personal
communication) resulted in o15% cell kill in our assay.7
Statistical analysis
To determine whether the peripheral CD33-antigen load was
different between patients that achieved complete remission
(either with or without full recovery of platelets2,3) and
nonresponders, a Mann–Whitney U-test using log-transformed
data was applied. Univariate analysis using age, FAB-type,
multidrug resistance efflux, ECOG performance status, duration
of CR1, and percentage BM blasts3 was performed using the
Mann–Whitney U-test. Unfortunately, karyotype data were not
completely available; inclusion of fusion gene transcript data
(CBFB-MYH11, PML-RARA, AML1-ETO) was not done due to
the very low number of patients (three out of 92) being positive
for one of these translocation-associated fusion gene transcripts.
Multivariate analysis, including all indicated variables that were
significant in the univariate analysis, was performed by logistic
regression. In all tests, a P-value of less then 0.05 was
considered significant.
Results and discussion
High peripheral CD33-antigen load is an independent
prognostic factor
To evaluate whether a high peripheral CD33-antigen load was
related to clinical outcome, we analyzed the CD33-antigen load
in PB of 92 patients enrolled in the European phase-II protocols.
The mean peripheral CD33-antigen load was significantly lower
in patients who achieved complete remission than in non-
responders (mean log(peripheral CD33-antigen load)7s.d.:
3.6770.85 vs 4.5870.97; Table 1). Further statistical analysis
using age, FAB-type, multidrug resistance efflux, ECOG
performance status, duration of CR1, and percentage BM blasts3
showed that duration of CR1 and percentage BM blasts were
significant prognostic markers as well (Table 1). However,
Figure 2 Relation between CD33 saturation and gemtuzumab-
induced cell kill. (a) CD33 saturation of AML193 cells in relation to
gemtuzumab concentration (mean7s.d.; n¼ 3). For CD33 saturation
levels 490% (as observed in PB), a gemtuzumab concentration of at
least 0.2 mg/ml was needed. For CD33 saturation levels of 40–90% (as
observed in BM), gemtuzumab concentrations of 0.01–0.1mg/ml (ie
two- 20-fold lower) were needed. The dotted lines indicate the mean
CD33 saturation level in BM (74%) or PB (92%) and the corresponding
gemtuzumab concentration. Comparable data were obtained for
granulocytes (CD33þ (low); n¼3) and monocytes (CD33þ (high);
n¼ 3). (b) Lysis of AML193 cells in relation to gemtuzumab
concentration (mean7s.d.; n¼3). Lysis was determined using a 51Cr
release assay after incubation with various gemtuzumab concentra-
tions for 24 or 40 h.7,8 The steep increase in cell kill observed at
gemtuzumab concentration ranging from 0.1 to 2.5 mg/ml (fromo5 to
445% cell kill) is assumed to be gemtuzumab-specific, because the
vast majority of cell kill can be inhibited by addition of an excess of
CD33-antibody.7 At higher gemtuzumab concentrations, also CD33-
independent uptake of gemtuzumab may be involved.7 (c) Relation
between CD33 saturation and cell lysis of AML193 cells. The
combined data of (a) and (b) show that CD33 saturation levels
490% (as observed in PB; CD33 saturation window PB) resulted in
10–50% lysis. CD33 saturation levels o90% as observed in BM
(CD33 saturation window BM) result in o5% lysis.
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multivariate analysis showed that only the log(peripheral CD33-
antigen load) was an independent prognostic factor (Table 1). In
accordance with our data, the likelihood of achieving response to
gemtuzumab therapy was shown to be associated with lower
levels of CD33-positive leukemic blasts in PB3 or BM.2 Thus, high
peripheral CD33-antigen loads reduce treatment efficacy, prob-
ably by consuming gemtuzumab and thereby reducing the
gemtuzumab amount available for leukemic cells in BM. This
may result in reduced CD33 saturation on AML blast cells present
in BM and subsequently in inefficient induction of cell kill.
CD33 saturation on AML blast cells present in
BM is reduced
To investigate whether peripheral gemtuzumab consumption
indeed could reduce the gemtuzumab amount available for
leukemic cells in BM, we analyzed BM samples obtained 24 h
after gemtuzumab infusion. As shown in Figure 1a, prior to
gemtuzumab infusion only background saturation levels
(o20%) were observed in PB and BM. In PB, near-complete
CD33 saturation was observed at 6 h (data not shown) and at
24 h after gemtuzumab infusion (Figure 1a). In contrast, CD33
saturation in BM was significantly lower and ranged from 42 to
90%. Apparently, penetration of gemtuzumab (given at a dose of
9 mg/m2) into BM is not sufficient to saturate completely CD33-
antigens on AML blasts present in BM 24 h after gemtuzumab
infusion.
Preliminary analysis showed that the degree of reduced CD33
saturation in BM was only partly related to the peripheral CD33-
antigen load (data not shown), but was related to the CD33
expression level of the AML blasts in BM (Figure 1b). It will be
interesting to analyze the relationship between peripheral
CD33-antigen loads and CD33 saturation in BM in future
Figure 3 Parameters affecting the efficacy of gemtuzumab treatment. (a) At the cellular level, several parameters affecting gemtuzumab’s
efficacy can be recognized. The maximal gemtuzumab binding is dependent on the CD33 expression level of the cell (1). After gemtuzumab
infusion, CD33-antigens are rapidly saturated (2) and the gemtuzumab/CD33-antigen complexes are subsequently internalized (3). In lysosomes,
the acid-labile linker is hydrolyzed, followed by activation of calicheamicin and degradation of the antibody part of gemtuzumab (4). Upon
internalization, new CD33-antigens are rapidly expressed on the cell membrane (5) and can bind gemtuzumab (6), resulting in an ongoing process
of gemtuzumab internalization as long as saturating gemtuzumab concentrations are present. Calicheamicin can be pumped out of the cell by drug
pumps such as Pgp and MRP1 (7). Active calicheamicin enters the nucleus and can induce double-strand DNA breaks (8), finally resulting in the
induction of cell death. (b) Besides cellular parameters, systemic parameters are involved in the efficacy of gemtuzumab. These particularly
include the peripheral CD33-antigen load, which determines the amount of gemtuzumab that is consumed by the myeloid cells in PB and
consequently the amount of gemtuzumab available for binding to CD33-antigens in BM. CD33 saturation in BM also appeared to be affected by
the total CD33-antigen load in BM.
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protocols involving gemtuzumab in more detail. However, it
should be kept in mind that the final CD33 saturation level in BM
is not only affected by the peripheral CD33-antigen load, but may
also be dependent on the total CD33-antigen load in BM.
Complete saturation is required for efficient cell kill
After binding to CD33-antigens, gemtuzumab is rapidly inter-
nalized and the calicheamicin derivate is intracellularly
activated.1,6 Importantly, continuous renewed expression of
CD33-antigens on the cellular surface of myeloid cells
significantly increases the amount of internalized gemtuzumab
as long as saturating levels of gemtuzumab are present.6
Therefore, the reduced CD33 saturation levels observed in BM
may result in severely reduced accumulation of gemtuzumab
into the cell, and thereby in inefficient induction of cell kill. To
evaluate whether reduced CD33 saturation levels indeed
resulted in less efficient induction of cell kill, myeloid cells
(monocytes, granulocytes, AML193 cells) were incubated with
gemtuzumab, and CD33 saturation and/or cell kill were
determined. As shown in Figure 2, CD33 saturation and
gemtuzumab-induced cell kill were both concentration depen-
dent. Of importance, the combined CD33 saturation and cell
kill data indicate that CD33 saturation levelso90% (as found in
BM) resulted in a dramatic decrease in cell lysis (o5%;
Figure 2c). Thus, gemtuzumab concentrations resulting in
near-complete CD33 saturation levels (490%) are required for
efficient cell kill. In our opinion, this reflects the continuous
process of saturation, internalization, and new expression of
CD33-antigens,6,9 resulting in the progressive accumulation of
gemtuzumab (and consequently calicheamicin) in the cell (see
Figure 3a). In agreement with this, the steep increase in
gemtuzumab-induced cell kill (from 15 to 445%) is observed
in the gemtuzumab concentration range of 0.5–2.5mg/ml; at
these concentrations the vast majority of the gemtuzumab-
induced cell kill is CD33-mediated.7 Additionally, at such high
gemtuzumab concentrations (41 mg/ml) CD33-independent
uptake mechanisms (ie endocytosis) may occur.7 Irrespective
whether gemtuzumab is taken up by the cell via CD33-
dependent internalization or via CD33-independent mechan-
isms, our data indicate that high gemtuzumab concentrations
(those resulting in near-complete CD33 saturation) are needed
for efficient cell kill. The reduced CD33 saturation levels in BM
(Figure 1) indicate that the gemtuzumab concentration in BM is
relatively low, and consequently cell kill will be reduced
(Figure 2).
Implications for gemtuzumab therapy
In this report, we show that a high peripheral CD33-antigen load
is an independent adverse prognostic factor in AML patients
treated with gemtuzumab. Our data indicate that a high
peripheral CD33-antigen load consumes a large part of the
gemtuzumab dose (9 mg/m2), which results in reduced gemtu-
zumab penetration in BM (Figure 3b). As a consequence, CD33
saturation of AML blast cells present in BM is incomplete, which
drastically hampers subsequent cell kill.
For efficient killing of AML blasts in BM, the effective
gemtuzumab dose should be increased in order to reach
consistently high CD33 saturation levels. This can be done by
increasing the dose of 9 mg/m2 or by giving repeated doses at
subsequent days,9 which may however be complicated by the
increase of severe side effects, including VOD.4 Alternatively and
preferably, gemtuzumab could be administered after reduction of
the leukemic cell burden by classical chemotherapy. However,
so far, in most studies applying gemtuzumab-based combination
regimens, gemtuzumab is given prior to or simultaneously with
chemotherapy.10–15 The use of gemtuzumab in a postremission
regimen, combined with chemotherapy, has recently shown to be
feasible and well-tolerated but needs further investigation.16 To
further improve the intracellular accumulation of gemtuzumab,
drug efflux modulators such as cyclosporine A may be added to
the treatment regimen as well.13–18 A better understanding of
gemtuzumab’s mechanism of action will hopefully contribute to
the design of future treatment protocols that maximally exploit the
potencies of gemtuzumab.
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